177 related articles for article (PubMed ID: 22058195)
21. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
24. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
Daubon T; Rochelle T; Bourmeyster N; Génot E
Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
[TBL] [Abstract][Full Text] [Related]
25. Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.
Price CM; Rassool F; Shivji MK; Gow J; Tew CJ; Haworth C; Goldman JM; Wiedemann LM
Blood; 1988 Nov; 72(5):1829-32. PubMed ID: 3179449
[TBL] [Abstract][Full Text] [Related]
26. Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
Hickey FB; Cotter TG
Eur J Haematol; 2006 May; 76(5):369-83. PubMed ID: 16494625
[TBL] [Abstract][Full Text] [Related]
27. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.
Kelliher M; Knott A; McLaughlin J; Witte ON; Rosenberg N
Mol Cell Biol; 1991 Sep; 11(9):4710-6. PubMed ID: 1875948
[TBL] [Abstract][Full Text] [Related]
28. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
[TBL] [Abstract][Full Text] [Related]
30. Chronic Myelogenous Leukemia with Double Philadelphia Chromosome and Coexpression of p210 and p190 Fusion Transcripts.
Cruz SSD; Seabra AD; Macambira LHR; Carneiro DM; Nunes PF; Pontes TB; Mello-Junior FAR; Leão LBC; Cordeiro FNCDS; Carneiro TX; Moreira-Nunes CA; Burbano RMR
Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456386
[TBL] [Abstract][Full Text] [Related]
31. Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Urbano A; Koc Y; Foss FM
Leukemia; 1998 Jun; 12(6):930-6. PubMed ID: 9639422
[TBL] [Abstract][Full Text] [Related]
32. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
LaMontagne KR; Hannon G; Tonks NK
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14094-9. PubMed ID: 9826659
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
Yu W; Sun X; Tang H; Tao Y; Dai Z
Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348
[TBL] [Abstract][Full Text] [Related]
34. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
36. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
37. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
38. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
39. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
Zhu YF; Wang YZ; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
[TBL] [Abstract][Full Text] [Related]
40. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
Thomas EK; Cancelas JA; Zheng Y; Williams DA
Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
